公开(公告)号：US20170022150A1

公开(公告)日：2017-01-26

申请号：US15216124

申请日：2016-07-21

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Yao-Ling Qiu ,  Wei Li ,  Hui Cao ,  Meizhong Jin ,  Jorden Kass ,  Xuri Gao ,  Xiaowen Peng ,  Yat Sun Or

IPC: C07C235/56 ,  A61K45/06 ,  A61K31/265 ,  C07C233/66 ,  A61K31/4164 ,  A61K31/277 ,  C07C271/12 ,  A61K31/27 ,  C07D233/64 ,  A61K31/167 ,  C07C255/60

CPC classification number: C07C235/56 ,  A61K45/06 ,  C07C233/66 ,  C07C235/42 ,  C07C255/58 ,  C07C255/60 ,  C07C271/12 ,  C07C271/28 ,  C07C2601/02 ,  C07D233/64 ,  C07D233/88

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A1-Y-A2-Z-L-R  (I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract translation: 其抑制由乙型肝炎病毒（HBV）编码的蛋白质或干扰乙型肝炎病毒的HBV生命周期的功能，并且也可用作抗病毒剂。 本发明还涉及包含用于给患有HBV感染的受试者的上述化合物的药物组合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HBV感染的方法。

公开(公告)号：US20160332996A1

公开(公告)日：2016-11-17

申请号：US15152647

申请日：2016-05-12

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Yao-Ling Qiu ,  Wei Li ,  Hui Cao ,  Meizhong Jin ,  Xuri Gao ,  Xiaowen Peng ,  Jorden Kass ,  Yat Sun Or

IPC: C07D405/12 ,  A61K31/454 ,  A61K45/06 ,  C07D231/38 ,  C07D403/12 ,  C07D211/46 ,  A61K31/445 ,  C07D401/14 ,  C07D231/40 ,  C07D401/12 ,  A61K31/415

CPC classification number: C07D405/12 ,  A61K31/415 ,  A61K31/4155 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/5377 ,  A61K45/06 ,  C07D211/46 ,  C07D231/38 ,  C07D231/40 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A-Y—Z-L-R1  (I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract translation: 其抑制由乙型肝炎病毒（HBV）编码的蛋白质或干扰乙型肝炎病毒的HBV生命周期的功能，并且也可用作抗病毒剂。 本发明还涉及包含用于给患有HBV感染的受试者的上述化合物的药物组合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HBV感染的方法。